LifeBridge Innovations
Oncology Therapeutics · Health Care
$3.4Mlatest round · Convertible Note · Jun 2025 · 16 mo ago
1backers · Charlottesville Angel Network
50+team · employees, estimated range
2022founded
Overview
FUTURE HOPE FOR STAGE 4 PATIENTS The team at Lifebridge 10000 continues building its patent-pending LB10000 device, built from the ground up for late-stage cancer patients with metastatic disease in two or more locations on the body at once.
Funding and backers
Total raised
$3.4M
2 rounds on record
Latest round
$3.4M
Convertible Note · Jun 2025 · 16 mo ago
Team
51-200
employees, estimated range
Backers
1
Charlottesville Angel Network
The money's age
Due for its next round
16 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 24, 2025
Raised a round Convertible Note $3.4M · SEC Form D
Jul 12, 2022
New executive Rick Rotondo, Executive Officer · SEC Form D
Jun 7, 2022
Raised a round Venture round $45k · SEC Form D
2022
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Convertible Note | Jun 2025 | $3.4M | — | SEC Form D |
| Venture round | Jun 2022 | $45k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | LifeBridge 10000, LLC | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Mike BlackExecutive OfficerSEC Form D
Peter TraversExecutive Officer, DirectorSEC Form D
Rick RotondoExecutive OfficerSEC Form D
Ken WatkinsExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Innovating life-changing medicines for cancer patients. At Kumquat, we're on a mission to transform cancer treatment by delivering durable…
Focused on oncology, we are committed to continuously innovating and developing new breakthrough cancer drugs, aiding cancer patients to…
Cairn Therapeutics: Targeting the Cancer, just the cancer. Making cancer treatment simpler and safer with CT-262.
Eisbach Bio is a clinical-stage biotechnology company developing next-generation cancer therapies with its proprietary ALLOS platform.
Alterome is a clinical-stage precision oncology company developing first-in-class, alteration-specific therapies for AKT E17K- and…
The Next Generation in. OncoSenX is a late stage pre-clinical cancer company headquartered in Seattle, Washington. OncoSenX targets solid…
People
Mike Black
Executive Officer
Peter Travers
Executive Officer, Director
Rick Rotondo
Executive Officer
Ken Watkins
Executive Officer
Jim LaBate
Director
Yung-Ping Yeh
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Charlottesville Angel NetworkVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Longwood
United States
HQ
50-200 est. staff